Visit-to-visit variability of glycemia and vascular complications: the Hoorn Diabetes Care System cohort

[1]  Suhua Li,et al.  Visit-to-visit fasting plasma glucose variability is an important risk factor for long-term changes in left cardiac structure and function in patients with type 2 diabetes , 2019, Cardiovascular Diabetology.

[2]  P. Reaven,et al.  Glycemic Variation and Cardiovascular Risk in the Veterans Affairs Diabetes Trial , 2018, Diabetes Care.

[3]  E. Bonora,et al.  Haemoglobin A1c variability is a strong, independent predictor of all‐cause mortality in patients with type 2 diabetes , 2018, Diabetes, obesity & metabolism.

[4]  K. Utsunomiya,et al.  Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report , 2018, Cardiovascular Diabetology.

[5]  G. Salles,et al.  Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study , 2018, Cardiovascular Diabetology.

[6]  L. Donnelly,et al.  Characteristics of people with high visit‐to‐visit glycaemic variability in Type 2 diabetes , 2017, Diabetic medicine : a journal of the British Diabetic Association.

[7]  B. Shields,et al.  Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia , 2017, Diabetologia.

[8]  T. Subramaniam,et al.  Effect of long‐term glycemic variability on estimated glomerular filtration rate decline among patients with type 2 diabetes mellitus: Insights from the Diabetic Nephropathy Cohort in Singapore , 2017, Journal of diabetes.

[9]  B. Zinman,et al.  Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2) , 2017, Diabetologia.

[10]  G. Nijpels,et al.  The Hoorn Diabetes Care System (DCS) cohort. A prospective cohort of persons with type 2 diabetes treated in primary care in the Netherlands , 2017, BMJ Open.

[11]  Chun-Pai Yang,et al.  Variability of fasting plasma glucose increased risks of diabetic polyneuropathy in T2DM , 2017, Neurology.

[12]  P. Conlin,et al.  Identifying the independent effect of HbA1c variability on adverse health outcomes in patients with Type 2 diabetes , 2016, Diabetic medicine : a journal of the British Diabetic Association.

[13]  G. Nijpels,et al.  Time to insulin initiation and long-term effects of initiating insulin in people with type 2 diabetes mellitus: the Hoorn Diabetes Care System Cohort Study. , 2016, European Journal of Endocrinology.

[14]  E. Wan,et al.  Association of Hemoglobin A1c Levels With Cardiovascular Disease and Mortality in Chinese Patients With Diabetes. , 2016, Journal of the American College of Cardiology.

[15]  A. Schneider,et al.  Association of the average rate of change in HbA1c with severe adverse events: a longitudinal evaluation of audit data from the Bavarian Disease Management Program for patients with type 2 diabetes mellitus , 2016, Diabetologia.

[16]  M. Rutter,et al.  Long-term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review and Meta-analysis , 2015, Diabetes Care.

[17]  Y. Matsuyama,et al.  The combined effect of visit-to-visit variability in HbA1c and systolic blood pressure on the incidence of cardiovascular events in patients with type 2 diabetes , 2015, BMJ Open Diabetes Research and Care.

[18]  G. Papanicolaou,et al.  Valganciclovir for the Prevention of Complications of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation , 2015, Annals of Internal Medicine.

[19]  Mahboob Rahman,et al.  Chronic Kidney Disease , 2015, Annals of Internal Medicine.

[20]  Niansong Wang,et al.  HbA1C Variability and the Risk of Renal Status Progression in Diabetes Mellitus: A Meta-Analysis , 2014, PloS one.

[21]  Chun-Pai Yang,et al.  Visit-to-visit variability of fasting plasma glucose as predictor of ischemic stroke: competing risk analysis in a national cohort of Taiwan Diabetes Study , 2014, BMC Medicine.

[22]  M. Woodward,et al.  Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial , 2014, Diabetes Care.

[23]  Desmond E. Williams,et al.  Changes in diabetes-related complications in the United States, 1990-2010. , 2014, The New England journal of medicine.

[24]  Y. Matsuyama,et al.  Visit-to-visit variability in systolic blood pressure predicts development and progression of diabetic nephropathy, but not retinopathy, in patients with type 2 diabetes. , 2014, Journal of diabetes and its complications.

[25]  M. Blaha,et al.  Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. , 2013, JAMA.

[26]  Chia-Ing Li,et al.  Risks of diabetic nephropathy with variation in hemoglobin A1c and fasting plasma glucose. , 2013, The American journal of medicine.

[27]  G. Zoppini,et al.  Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study , 2013, Cardiovascular Diabetology.

[28]  Xilin Yang,et al.  Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry , 2013, Diabetes/metabolism research and reviews.

[29]  菅原 歩美.  HbA1c variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2 , 2013 .

[30]  S. Shin,et al.  HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study , 2012, Diabetologia.

[31]  H. Sone,et al.  HbA1c variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2 , 2012, Diabetologia.

[32]  Josef Coresh,et al.  Chronic kidney disease , 2012, The Lancet.

[33]  Y. Iwamoto,et al.  Fluctuations in HbA1c are associated with a higher incidence of cardiovascular disease in Japanese patients with type 2 diabetes , 2011, Journal of diabetes investigation.

[34]  G. L. Moneta.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2011 .

[35]  J. Danesh,et al.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. , 2010, Lancet.

[36]  E. Bonora,et al.  Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes? , 2009, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[37]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[38]  Mahboob Rahman,et al.  Chronic Kidney Disease , 2009, Annals of Internal Medicine.

[39]  Supplemental Tables,et al.  KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). , 2009, Kidney international. Supplement.

[40]  E. Bonora,et al.  Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study , 1995, Diabetologia.

[41]  L. M. Lou-Arnal,et al.  Fasting plasma glucose variability as a risk factor of retinopathy in Type 2 diabetic patients. , 2003, Journal of diabetes and its complications.

[42]  R. de Marco,et al.  Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study. , 1997, Circulation.